BioWorld

Oct. 6, 2003

View Archived Issues

Cubist Signs Chiron As Ex-U.S. Partner For Cubicin Marketing

Read More

Ariad Gets $41M In Private Sale For Drug Development

Read More

Ligand Pulls Down $12.5M Through Royalty Agreement

Read More

Flamel Raises $62M Through Sale Of Its Common Shares

Read More

Receptor BioLogix Steering Lead Product Toward Gastric Cancer

Read More

Other News To Note

Read More

Asking For More Data, FDA Places Hold On DOV's Ocinaplon Phase III

The FDA placed a hold on DOV Pharmaceutical Inc.'s pivotal Phase III trial for an anti-anxiety candidate, asking for additional safety data. (BioWorld Today) Read More